glp 1 drugs for binge eating disorder GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders GLP-1 Therapy: An Emerging Tool

GLP-1 as a target for therapeutic intervention

Virta flexes to your organizations weight loss strategy Virta for Weight Loss GLP-1 alternative GLP-1 companion Virta for Weight Loss+ Combo therapy Built in off-ramp Works with preferred Rx fulfillment strategy 0% GLP-1 Trend

The US FDA approved the first GLP-1RA exenatide (Byetta) for the treatment of T2DM in 2005

Am J Physiol Endocrinol Metab 294(5):E846E852 Chedid V, Vijayvargiya P, Carlson P, Van Malderen K, Acosta A, Zinsmeister A et al (2018) Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: a pilot pharmacogenetics study

In individuals with obesity, this tissue expands and begins to produce excessive amounts of cytokines, which are proteins critical in regulating the immune system and inflammation

Accessed 16 Aug 2025 Mollan SP, Mitchell JL, Ottridge RS et al (2021) Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension